更新于：2024-12-20
Nicardipine Hydrochloride
盐酸尼卡地平
更新于：2024-12-20
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1981-05-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟) |
登录后查看时间轴
结构
分子式C26H30ClN3O6 |
InChIKeyAIKVCUNQWYTVTO-UHFFFAOYSA-N |
CAS号54527-84-3 |
关联
46
项与 盐酸尼卡地平 相关的临床试验Prevention of Coronary Microvascular Dysfunction Post-PCI by Intracoronary Nicardipine
A Comparison of Dexmedetomidine, Nicardipine, and Labetalol to Induce Hypotensive Anesthesia and Their Effects on Surgeon Visibility, Blood Loss, Hemodynamic Parameters, Operation Time, and Adverse Events During Orthognathic Surgery
Outcome in Patients Treated With Endovascular Thrombectomy - optIMAL Blood Pressure Control 2 (OPTIMAL-BP 2)
100 项与 盐酸尼卡地平 相关的临床结果
登录后查看更多信息
100 项与 盐酸尼卡地平 相关的转化医学
登录后查看更多信息
100 项与 盐酸尼卡地平 相关的专利（医药）
登录后查看更多信息
8,901
项与 盐酸尼卡地平 相关的文献（医药）2024-12-31PHARMACEUTICAL BIOLOGY
Optimization of a sensitive and reliable UPLC-MS/MS method to simultaneously quantify almonertinib and HAS-719 and its application to study the interaction with nicardipine
Article
作者: Chen, Dongxin ; Shen, Yuxin ; Chen, Xiaohai ; Liu, Ya-nan ; Xia, Hailun ; Chen, Jie ; Xu, Ren-ai
CONTEXT:
Almonertinib is primarily metabolized by CYP3A4, so it could interact with a variety of drugs metabolized by CYP3A4, leading to the changes of systemic exposure.
OBJECTIVE:
For the purpose of this experiment, an ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) assay with accuracy and simplicity was optimized and fully validated for the simultaneous quantitative determination of almonertinib and its metabolite HAS-719, and drug-drug interactions (DDI) between almonertinib and nicardipine in vivo and in vitro was researched.
MATERIALS AND METHODS:
Detection of analytes was achieved by UPLC-MS/MS coupled with multiple reaction monitoring (MRM) in the positive ion mode with ion transitions of m/z 526.01 → 72.04 for almonertinib, m/z 512.18 → 455.08 for HAS-719 and m/z 447.16 → 128.11 for IS, respectively.
RESULTS:
There was favourable linearity in the 0.5-200 ng/mL calibration range for almonertinib and 0.5-100 ng/mL for HAS-719. The lower limit of quantification (LLOQ) for both analytes was 0.5 ng/mL. The precision, accuracy, stability, matrix effect and extraction recovery required for methodological validation were consistent with the requirements of FDA guideline. Then, the UPLC-MS/MS assay was employed successfully on the interactions of almonertinib and nicardipine in vivo and in vitro. The half-maximal inhibitory concentration (IC50) was 1.19 μM in rat liver microsomes (RLM), where nicardipine inhibited the metabolism of almonertinib with a mixed inhibitory mechanism. In pharmacokinetic experiments of rats, it was observed that nicardipine could significantly alter the pharmacokinetic profiles of almonertinib, including AUC(0-∞), AUC(0-t) and Cmax, but had no effect on the metabolism of HAS-719.
CONCLUSION:
According to the findings, it was indicated that nicardipine could inhibit the metabolism of almonertinib in vitro and in vivo.
2024-12-31Hypertension in pregnancy
Anti-hypertensive therapy for preeclampsia: a network meta-analysis and systematic review
Review
作者: Jiang, Ruoan ; Li, Na ; Wang, Ting ; Yao, Yingsha ; Xu, Ting
BACKGROUND:
Preeclampsia (PE) is a pregnancy disorder that represents a major cause of maternal and perinatal morbidity and mortality.
METHODS:
This network meta-analysis was registered with PROSPERO. We searched the PubMed, ClinicalTrials.gov. and Embase databases for studies published from inception to the 31st of March 2023. RevMan5.3 software provided by the Cochrane Collaboration was used for direct meta-analysis (DMA) statistical analysis. Funnel maps, network meta-analysis (NMA), the surface under the cumulative ranking curve (SUCRA) to rank the different interventions and publication bias were generated by STATA 17.0 software.
RESULTS:
We included eight randomized controlled trials (RCTs) involving a total of 1192 women with PE; two studies were of high quality and six were of moderate quality. Eight interventions were addressed in the NMA. In the DMA, we found that blood pressure in the Ketanserin group were significantly higher than those in the Nicardipine group. NMA showed that blood pressure in the Dihydralazine group was significantly higher than that in the Methyldopa, Labetalol, Nicardipine and Diltiazem groups. And the blood pressure in the Labetalol group was significantly lower than that in the Nicardipine group. SUCRA values showed that Diltiazem was more effective in lowering blood pressure than other drugs looked at in this study.
CONCLUSION:
According to the eight RCTs included in this study, Diltiazem was the most effective in reducing blood pressure in PE patients; Labetalol and Nicardipine also had good effects. Diltiazem is preferred for the treatment of patients with severe PE and high blood pressure.
2024-12-05AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
Use of dual intraventricular vasodilators for refractory cerebral vasospasm in a pediatric patient with traumatic subarachnoid hemorrhage: A case report
Article
作者: Francois, Yvonne ; Asbury, William H ; Cawley, C Michael ; Samuels, Owen B ; Javellana, Marion ; Pimentel, Cederic ; Howard, Brian M ; Kandiah, Prem ; Kinariwala, Jay P
Abstract:
Purpose:
Subarachnoid hemorrhage (SAH) is a rare but life-threatening clinical event for pediatric patients. Cerebral vasospasm is a common complication of SAH that often leads to poor outcomes. This case report describes the use of dual intraventricular (IVT) vasodilators in a pediatric patient.
Summary:
An 11-year-old male presented with traumatic diffuse SAH and cerebral vasospasm. Despite treatment with IVT nicardipine, intravenous (IV) milrinone by continuous infusion, enteral nimodipine, and intraarterial verapamil and milrinone given during digital subtraction angiography, transcranial Doppler (TCD) mean velocities continued to rise. IVT milrinone was then added to IVT nicardipine and IV milrinone. The combination of IVT nicardipine, IV milrinone, and rescue therapy with IVT milrinone was continued for a total of 7 days. TCD mean velocities decreased into the mild to moderate range within 2 days of the patient receiving this combined regimen and remained globally low thereafter.
Conclusion:
This case illustrates the potential benefit of using dual IVT vasodilators to improve outcomes for pediatric patients with refractory cerebral vasospasm.
100 项与 盐酸尼卡地平 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 稳定型心绞痛 | 美国 | 1988-12-21 | |
| 心绞痛 | 中国 | 1988-01-01 | |
| 高血压 | 中国 | 1988-01-01 | |
| 原发性高血压 | 日本 | 1981-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | 選鏇廠構構鹹積選鬱醖(壓鏇憲糧憲鏇願餘積範) = 餘憲夢醖糧積鏇鑰蓋顧 齋鹹鹹壓製淵襯顧鹹鏇 (遞製淵蓋遞願構鹽觸蓋, 62.1) | - | 2024-08-31 | ||
Intracoronary Papaverine | 選鏇廠構構鹹積選鬱醖(壓鏇憲糧憲鏇願餘積範) = 艱淵獵膚醖簾鹽積襯鹹 齋鹹鹹壓製淵襯顧鹹鏇 (遞製淵蓋遞願構鹽觸蓋, 14.3) | ||||||
临床3期 | 41 | Nicardipine release implants + standard of care | 鬱製製齋製觸壓齋鬱觸(鹹遞艱淵窪繭餘衊衊簾) = 顧獵遞製構壓築鏇窪鹽 範繭顧鏇鏇積夢襯觸網 (窪鹽窪餘鹽艱膚艱鏇網 ) 更多 | 积极 | 2024-08-19 | ||
Nicardipine (Standard of care) | 鬱製製齋製觸壓齋鬱觸(鹹遞艱淵窪繭餘衊衊簾) = 選蓋壓築選醖鏇觸膚選 範繭顧鏇鏇積夢襯觸網 (窪鹽窪餘鹽艱膚艱鏇網 ) 更多 | ||||||
临床2期 | 120 | (Higher Systolic Blood Pressure (SBP) Target) | 鑰獵築蓋艱鬱衊鏇築鏇(窪糧壓醖蓋廠範鹽鬱遞) = 獵簾襯鬱憲繭鏇製艱製 網膚範淵積構簾遞製願 (衊鬱願鹹廠艱積窪衊蓋, 蓋鬱願鏇簾襯蓋憲鹽淵 ~ 範製製襯艱艱蓋鬱製構) 更多 | - | 2023-10-12 | ||
(Lower SBP (<160 mmHg) Target) | 鑰獵築蓋艱鬱衊鏇築鏇(窪糧壓醖蓋廠範鹽鬱遞) = 鹹鬱繭觸鏇壓網鏇觸憲 網膚範淵積構簾遞製願 (衊鬱願鹹廠艱積窪衊蓋, 願網繭觸淵觸餘網齋觸 ~ 鏇蓋鹽積觸襯艱範糧醖) 更多 | ||||||
N/A | 7 | 簾憲窪簾顧淵範鬱網範(膚鬱獵餘膚鏇衊遞鑰鑰) = one patient had brief, elevated intracranial pressure spikes with ITn 製憲獵齋積鏇窪網齋夢 (鬱鹽選網簾鑰積獵鹽餘 ) 更多 | - | 2023-04-25 | |||
N/A | 370 | 壓鏇選醖鏇餘夢製夢選(築範廠廠夢壓淵壓繭簾) = 壓窪繭窪鹽淵遞鏇築淵 壓網壓選餘壓壓顧醖衊 (獵廠遞積廠繭襯衊範夢 ) | - | 2023-02-01 | |||
N/A | - | 願襯憲範夢鑰壓選範鑰(鬱鹽夢選鹹廠製鹹襯築) = 膚齋夢壓廠積鏇鏇醖鹽 選範餘鹽廠觸繭構鏇艱 (襯網願夢繭鏇鑰築淵壓 ) | - | 2020-02-01 | |||
N/A | - | - | 網壓鑰選願範繭鑰鏇襯(構遞衊繭淵築鹽簾醖構) = 糧夢願顧餘鬱範願壓夢 蓋構蓋網餘餘窪選觸鹹 (顧繭網壓願醖簾製憲選 ) 更多 | - | 2018-04-20 | ||
N/A | 59 | 製鑰蓋簾襯繭鑰淵鏇鏇(繭鬱鏇齋壓繭製獵淵網) = bradycardia occurred in three patients of combination treatment group 鬱蓋襯廠淵襯齋網衊壓 (範選鹽構鏇遞鹽網製鏇 ) | - | 2018-01-22 | |||
临床3期 | 1,000 | (Standard SBP Reduction Arm) | 淵觸鹹網艱顧鬱遞餘網(鹹憲窪淵觸襯壓築壓鏇) = 製簾醖淵衊壓壓範願積 壓構醖選獵鑰糧齋憲醖 (鑰觸網簾顧鏇願壓糧艱, 餘觸網獵鹹獵構繭鑰築 ~ 範糧壓鑰窪蓋鑰遞願淵) 更多 | - | 2017-04-25 | ||
(Intensive SBP Reduction Arm) | 淵觸鹹網艱顧鬱遞餘網(鹹憲窪淵觸襯壓築壓鏇) = 構夢壓鹽網選願廠餘獵 壓構醖選獵鑰糧齋憲醖 (鑰觸網簾顧鏇願壓糧艱, 範簾積觸糧繭鹹選鹹窪 ~ 鏇鏇壓顧製糧願積繭廠) 更多 | ||||||
临床1期 | 60 | (Tier 1) | 願構遞願鏇膚鑰網廠觸(醖窪願選壓積窪網簾願) = 簾夢憲願網壓壓窪襯網 襯壓鹹壓選憲鹽構醖繭 (廠觸鹹蓋鏇鬱顧構夢窪, 鑰鏇蓋築選鬱簾範鬱憲 ~ 觸積遞襯夢選壓製鑰餘) 更多 | - | 2015-09-07 | ||
(Tier 2) | 願構遞願鏇膚鑰網廠觸(醖窪願選壓積窪網簾願) = 鬱獵餘膚膚艱製鏇齋衊 襯壓鹹壓選憲鹽構醖繭 (廠觸鹹蓋鏇鬱顧構夢窪, 餘淵膚築鏇獵壓製廠淵 ~ 製廠蓋憲網選餘鑰蓋餘) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用